Sienna Biopharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNNAQ research report →
About the company
Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm dedicated to discovering and advancing pharmaceutical treatments across diverse therapeutic fields. Its primary focus involved crafting therapies within immunology and inflammation, specifically targeting particular tissue pathways, notably in the skin.
- CEO
- David E. I. Pyott
- IPO
- 2017
- Employees
- 13
- HQ
- Westlake Village, CA, US
Price Chart
- Market Cap
- $3.09K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.24
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.78%
- ROIC
- -92.02%
- Revenue
- $0 · 0.00%
- Net Income
- $-73,314,000 · -45.05%
- EPS
- $-3.59 · 30.83%
- Op Income
- $-76,498,000
- FCF YoY
- -49.26%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.61
- Avg Volume
- 3.16K
Get TickerSpark's AI analysis on SNNAQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SNNAQ coverage
Recent articles, reports, and earnings notes.
No research on SNNAQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SNNAQ report →Similar companies
Peers in the same neighborhood.